GlobalData on MSN6d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Zacks.com on MSN6d
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
The Pharma Letter5d
BRIEF—Andembry approved to prevent angioedema attacks by MHRA
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...
The Age6d
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
“We had no idea what it was,” says Wardman. She was terrified. The swollen hand of a patient with hereditary angioedema.Credit: HAE Australasia / Supplied As she hit puberty, the attacks ...
BioWorld1d
TGA clears CSL’s garadacimab to prevent hereditary angioedema
Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...
Astria Therapeutics Receives Buy Rating Due to Promising Clinical Developments and Strategic Market Positioning
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), with ...
American Association of Individual Investors13h
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Healio5d
Top in allergy/asthma: Passing of Marcus Maurer, MD; briquilimab for chronic urticaria
The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology ...